Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.1K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.1K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.0K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.0K
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

617
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
617
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

364
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
364
Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

920
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
920
Predicting Molecular Geometry02:27

Predicting Molecular Geometry

45.7K
VSEPR Theory for Determination of Electron Pair Geometries
45.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Myotonia Mimicking Paroxysmal Dystonia: Two Cases of SCN4A Temperature-Sensitive Sodium Channelopathy.

Movement disorders clinical practice·2026
Same author

Dystonia in Parkinson's disease: Clinical characteristics and predictors of treatment response.

Parkinsonism & related disorders·2026
Same author

A sacred prelude to aphasia: Demystifying a diagnostic trinity.

Parkinsonism & related disorders·2026
Same author

Bridging the global Parkinson's divide: Technology as a structural solution for equitable and brain health-integrated care.

Journal of Parkinson's disease·2026
Same author

Beyond hypoxia: Systemic acidemia and respiratory insufficiency in Lance-Adams syndrome.

Journal of the neurological sciences·2026
Same author

Stereotypies misdiagnosed as functional neurological disorder in late-onset Niemann-Pick C.

Parkinsonism & related disorders·2026

Related Experiment Video

Updated: Jan 28, 2026

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
06:07

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease

Published on: June 23, 2023

2.2K

Clinical Parkinson disease subtyping does not predict pathology

Alberto J Espay1, Connie Marras2

  • 1UC James J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders, UC Gardner Neuroscience Institute, Department of Neurology, University of Cincinnati, Cincinnati, OH, USA. alberto.espay@uc.edu.

Nature Reviews. Neurology
|February 22, 2019
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.4K
The 6-hydroxydopamine Rat Model of Parkinson's Disease
08:10

The 6-hydroxydopamine Rat Model of Parkinson's Disease

Published on: October 27, 2021

12.9K

Related Experiment Videos

Last Updated: Jan 28, 2026

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
06:07

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease

Published on: June 23, 2023

2.2K
Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.4K
The 6-hydroxydopamine Rat Model of Parkinson's Disease
08:10

The 6-hydroxydopamine Rat Model of Parkinson's Disease

Published on: October 27, 2021

12.9K